Edwards Lifesciences (EW) Deferred Taxes (2009 - 2026)

Edwards Lifesciences' Deferred Taxes history runs 18 years deep, the most recent figure standing at -$9.4 million for Q1 2026.

• On a quarterly basis, Deferred Taxes fell 138.68% year-over-year to -$9.4 million in Q1 2026; TTM through Mar 2026 was $83.9 million, a 73.1% decrease from a year earlier, with the FY2025 full-year figure at $117.6 million, down 63.64% from the prior year.
• Deferred Taxes slipped to -$9.4 million in Q1 2026 per EW's latest filing, from $54.4 million in the prior quarter.
• Across five years, Deferred Taxes topped out at $123.0 million in Q3 2024 and bottomed at -$9.4 million in Q1 2026.
• The 5-year median for Deferred Taxes is $51.8 million (2023), against an average of $56.4 million.
• Across the five-year window, Deferred Taxes surged 1287.18% in 2022 and plunged 138.68% in 2026, its largest moves.
• Year by year, Deferred Taxes stood at $105.8 million in 2022, then fell by 13.61% to $91.4 million in 2023, then climbed by 7.77% to $98.5 million in 2024, then sank by 44.77% to $54.4 million in 2025, then sank by 117.28% to -$9.4 million in 2026.
• Per Business Quant, the three latest EW Deferred Taxes figures stand at -$9.4 million (Q1 2026), $54.4 million (Q4 2025), and $18.0 million (Q3 2025).